A detailed history of Waters Parkerson & Co., LLC transactions in Amgen Inc stock. As of the latest transaction made, Waters Parkerson & Co., LLC holds 3,904 shares of AMGN stock, worth $1.31 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,904
Previous 3,904 -0.0%
Holding current value
$1.31 Million
Previous $1.12 Million 1.25%
% of portfolio
0.06%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$255.7 - $288.46 $127,850 - $144,230
500 Added 14.69%
3,904 $1.12 Million
Q2 2023

Aug 14, 2023

SELL
$214.27 - $253.37 $1,071 - $1,266
-5 Reduced 0.15%
3,404 $756,000
Q1 2023

May 02, 2023

BUY
$225.79 - $275.2 $1,128 - $1,376
5 Added 0.15%
3,409 $824,000
Q2 2022

Aug 01, 2022

SELL
$230.71 - $256.74 $34,606 - $38,511
-150 Reduced 4.22%
3,404 $828,000
Q1 2022

May 13, 2022

SELL
$219.27 - $242.57 $2,850 - $3,153
-13 Reduced 0.36%
3,554 $859,000
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $2,585 - $2,958
13 Added 0.37%
3,567 $802,000
Q4 2020

Feb 10, 2021

SELL
$216.38 - $257.67 $2,596 - $3,092
-12 Reduced 0.34%
3,554 $817,000
Q3 2020

Nov 16, 2020

BUY
$234.65 - $260.95 $2,815 - $3,131
12 Added 0.34%
3,566 $906,000
Q2 2020

Aug 13, 2020

SELL
$197.81 - $242.74 $24,528 - $30,099
-124 Reduced 3.37%
3,554 $838,000
Q3 2019

Nov 13, 2019

SELL
$174.11 - $208.62 $27,857 - $33,379
-160 Reduced 4.17%
3,678 $712,000
Q1 2019

May 13, 2019

SELL
$180.87 - $203.88 $633,045 - $713,580
-3,500 Reduced 47.7%
3,838 $729,000
Q4 2018

Feb 12, 2019

SELL
$178.4 - $208.25 $27,116 - $31,654
-152 Reduced 2.03%
7,338 $1.43 Million
Q3 2017

Nov 13, 2017

SELL
$167.29 - $191.0 $174,316 - $199,022
-1,042 Reduced 12.21%
7,490 $1.4 Million
Q2 2017

Aug 11, 2017

BUY
N/A
8,532
8,532 $1.47 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $179B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Waters Parkerson & Co., LLC Portfolio

Follow Waters Parkerson & Co., LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Waters Parkerson & Co., LLC, based on Form 13F filings with the SEC.

News

Stay updated on Waters Parkerson & Co., LLC with notifications on news.